Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
1(8%)
Results Posted
33%(3 trials)

Phase Distribution

Ph early_phase_1
1
8%
Ph not_applicable
1
8%
Ph phase_2
5
42%
Ph phase_1
4
33%
Ph phase_3
1
8%

Phase Distribution

5

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
1(8.3%)
Phase 1Safety & dosage
4(33.3%)
Phase 2Efficacy & side effects
5(41.7%)
Phase 3Large-scale testing
1(8.3%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(9)
Other(1)

Detailed Status

Completed9
unknown1
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (8.3%)
Phase 14 (33.3%)
Phase 25 (41.7%)
Phase 31 (8.3%)
N/A1 (8.3%)

Trials by Status

completed975%
unknown18%
not_yet_recruiting18%
active_not_recruiting18%

Recent Activity

1 active trials
Showing 5 of 12
not_yet_recruitingphase_2

Testing the SurVaxM Vaccine for Lung Cancer Prevention

NCT07169617
active_not_recruitingphase_2

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NCT02455557
unknownnot_applicable

KLH Challenge to Explore the Human Immune Response

NCT05876195
completedphase_1

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

NCT01176461
completedearly_phase_1

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

NCT01748747
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT07169617Phase 2

Testing the SurVaxM Vaccine for Lung Cancer Prevention

Not Yet Recruiting
NCT02455557Phase 2

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Active Not Recruiting
NCT05876195Not Applicable

KLH Challenge to Explore the Human Immune Response

Unknown
NCT01176461Phase 1

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Completed
NCT01748747Early Phase 1

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Completed
NCT01842139Phase 1

Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission

Completed
NCT00019682Phase 3

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

Completed
NCT00923195Phase 2

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Completed
NCT00089063Phase 2

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Completed
NCT00085189Phase 2

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Completed
NCT01012102Phase 1

EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors

Completed
NCT00004918Phase 1

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12